In a classic David Vs Goliath case, the US-based drugmaker Gilead that has made billions of dollars over its blockbuster range of Hepatitis C drugs is facing an unconventional challenger. Beacon Pharma, a little known Bangladeshi drugmaker, has emerged as the David to the Goliath that Gilead is.
Beacon has become the first generic drug company in the world to produce copycat versions of Gilead’s newly launched Epclusa (Sofosbuvir + Velpatasvir) — a drug used to treat all types of Hepatitis .. Read more
Source: economictimes.indiatimes.com